Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation DOI
Kai Xing, Yuan Chang,

Hao Jia

и другие.

Xenotransplantation, Год журнала: 2025, Номер 32(3)

Опубликована: Май 1, 2025

ABSTRACT Organ transplantation remains the foremost effective intervention for end‐stage organ failure. Nevertheless, scarcity of donors has resulted in prolonged waiting times countless patients globally. The advent xenografts presents a promising solution to shortage crisis. Although utilization long history, it is only recent years that breakthroughs genetically modified pigs have rendered successful xenotransplantation feasible option. In past 4 years, numerous subclinical and clinical trials involved from humans. However, outcomes been disappointing, necessitating reassessment basic preclinical research address emerging challenges. Furthermore, immunosuppressive therapies remain essential xenotransplantation. range agents, encompassing traditional immunosuppressants monoclonal antibodies such as anti‐CD154/CD40 antibodies, exhibits considerable diversity. most drug combination achieving optimal efficacy elusive. This review will offer succinct overview results trials. Moreover, highlight advancements strategies discuss potential future directions this field.

Язык: Английский

Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes DOI
Andrew Simonson, Joseph J. Zeppa, Allison N. Bucşan

и другие.

The Journal of Experimental Medicine, Год журнала: 2025, Номер 222(4)

Опубликована: Янв. 17, 2025

Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the route and dose from 5 × 105 CFUs ID to 107 i.v. resulted prevention of Mycobacterium tuberculosis (Mtb) infection TB disease highly susceptible nonhuman primates. Identifying immune mechanisms protection following will facilitate development more effective vaccines against TB. Here, we depleted lymphocyte subsets prior during Mtb challenge BCG-vaccinated macaques identify those necessary for protection. Depletion adaptive CD4 T cells, but not CD8αβ loss with increased burdens dissemination, indicating cells are critical BCG-mediated unconventional CD8α-expressing lymphocytes (NK innate CD4+CD8α+ double-positive cells) abrogated most BCG-immunized macaques, supporting further investigation into which these cell contribute after vaccination.

Язык: Английский

Процитировано

5

CD4 T cells and CD8α+ lymphocytes are necessary for intravenous BCG-induced protection against tuberculosis in macaques DOI Creative Commons
Andrew Simonson, Joseph J. Zeppa, Allison N. Bucşan

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Май 17, 2024

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the route dose from 5×105 CFU ID to 5×107 intravenous (IV) resulted prevention infection disease rigorous, highly susceptible non-human primate model TB. Identifying immune mechanisms protection for IV will facilitate development more effective vaccines against Here, we depleted select lymphocyte subsets vaccinated macaques prior Mtb challenge determine cell types necessary protection. Depletion CD4 T cells or all CD8α expressing lymphoycytes (both innate adaptive) loss most macaques, concomitant with increased bacterial burdens (~4-5 log10 thoracic CFU) dissemination infection. In contrast, depletion only adaptive CD8αβ+ did not significantly reduce disease. Our results demonstrate CD8α+ lymphocytes are critical BCG-induced protection, supporting investigation how eliciting these their functions can improve future TB vaccines.

Язык: Английский

Процитировано

4

Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation DOI
Kai Xing, Yuan Chang,

Hao Jia

и другие.

Xenotransplantation, Год журнала: 2025, Номер 32(3)

Опубликована: Май 1, 2025

ABSTRACT Organ transplantation remains the foremost effective intervention for end‐stage organ failure. Nevertheless, scarcity of donors has resulted in prolonged waiting times countless patients globally. The advent xenografts presents a promising solution to shortage crisis. Although utilization long history, it is only recent years that breakthroughs genetically modified pigs have rendered successful xenotransplantation feasible option. In past 4 years, numerous subclinical and clinical trials involved from humans. However, outcomes been disappointing, necessitating reassessment basic preclinical research address emerging challenges. Furthermore, immunosuppressive therapies remain essential xenotransplantation. range agents, encompassing traditional immunosuppressants monoclonal antibodies such as anti‐CD154/CD40 antibodies, exhibits considerable diversity. most drug combination achieving optimal efficacy elusive. This review will offer succinct overview results trials. Moreover, highlight advancements strategies discuss potential future directions this field.

Язык: Английский

Процитировано

0